IGSF10

Summary

IGSF10 (immunoglobulin superfamily member 10, HGNC:26384) is a protein-coding gene on chromosome 3q25.1, encoding Immunoglobulin superfamily member 10 (Q6WRI0). Involved in the control of early migration of neurons expressing gonadotropin-releasing hormone (GNRH neurons).

Predicted to be involved in regulation of neuron migration. Predicted to act upstream of or within ossification. Located in extracellular region.

Source: NCBI Gene 285313 — RefSeq curated summary.

At a glance

• Gene–disease (curated): disorder of sexual differentiation (Moderate, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 724 total
• MANE Select transcript: NM_178822

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26384
Approved symbol	IGSF10
Name	immunoglobulin superfamily member 10
Location	3q25.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25972, CMF608
Ensembl gene	ENSG00000152580
Ensembl biotype	protein_coding
OMIM	617351
Entrez	285313

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000282466, ENST00000489791, ENST00000493841, ENST00000495443, ENST00000497472, ENST00000857598, ENST00000934900

RefSeq mRNA: 7 — MANE Select: NM_178822 NM_001178145, NM_001178146, NM_001385060, NM_001385061, NM_001385062, NM_001385063, NM_178822

CCDS: CCDS3160

Canonical transcript exons

ENST00000282466 — 8 exons

Exon	Start	End
ENSE00001366871	151458516	151458710
ENSE00001368502	151444919	151449265
ENSE00001384465	151453384	151453774
ENSE00001385290	151457026	151457155
ENSE00001390390	151442984	151443884
ENSE00001890176	151436203	151438597
ENSE00003918128	151460946	151461061
ENSE00003920807	151460261	151460347

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 96.13.

FANTOM5 (CAGE): breadth broad, TPM avg 1.8528 / max 202.3538, expressed in 444 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45166	1.1175	275
45168	0.4843	184
45169	0.1762	50
45171	0.0287	9
45170	0.0235	10
45167	0.0103	5
45162	0.0078	4
45163	0.0045	3

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	96.13	gold quality
left ovary	UBERON:0002119	93.87	gold quality
kidney epithelium	UBERON:0004819	93.65	gold quality
right ovary	UBERON:0002118	93.20	gold quality
right lung	UBERON:0002167	92.50	gold quality
upper arm skin	UBERON:0004263	92.42	silver quality
skin of hip	UBERON:0001554	92.18	gold quality
decidua	UBERON:0002450	91.33	gold quality
left ventricle myocardium	UBERON:0006566	91.29	gold quality
lower lobe of lung	UBERON:0008949	90.42	gold quality
ovary	UBERON:0000992	90.03	gold quality
upper lobe of left lung	UBERON:0008952	89.61	gold quality
upper lobe of lung	UBERON:0008948	89.19	gold quality
lung	UBERON:0002048	88.01	gold quality
mucosa of paranasal sinus	UBERON:0005030	87.59	gold quality
secondary oocyte	CL:0000655	87.51	gold quality
gall bladder	UBERON:0002110	86.82	gold quality
bronchial epithelial cell	CL:0002328	86.65	gold quality
oocyte	CL:0000023	86.28	gold quality
cardiac atrium	UBERON:0002081	85.75	gold quality
bronchus	UBERON:0002185	85.70	gold quality
mammary duct	UBERON:0001765	85.64	gold quality
right uterine tube	UBERON:0001302	85.63	gold quality
epithelium of mammary gland	UBERON:0003244	85.59	gold quality
right atrium auricular region	UBERON:0006631	85.30	gold quality
upper leg skin	UBERON:0004262	84.93	gold quality
thoracic mammary gland	UBERON:0005200	84.65	gold quality
myocardium	UBERON:0002349	84.59	silver quality
sperm	CL:0000019	84.52	gold quality
parotid gland	UBERON:0001831	84.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

78 targeting IGSF10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917

Literature-anchored findings (GeneRIF, showing 3)

• These data strongly suggest that mutations in IGSF10 cause delayed puberty in humans, and points to a common genetic basis for conditions of functional hypogonadotropic hypogonadism (HH). (PMID:27137492)
• SEMA3A and IGSF10 Are Novel Contributors to Combined Pituitary Hormone Deficiency (CPHD). (PMID:32612575)
• IGSF10 inhibits the metastasis of lung adenocarcinoma via the Spi-B/Integrin-beta1 signaling pathway. (PMID:38622980)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	igsf10	ENSDARG00000077497
mus_musculus	Igsf10	ENSMUSG00000036334
rattus_norvegicus	Igsf10	ENSRNOG00000013917

Paralogs (36): CNTN1 (ENSG00000018236), CDON (ENSG00000064309), NEO1 (ENSG00000067141), SDK2 (ENSG00000069188), IGSF9B (ENSG00000080854), IGSF9 (ENSG00000085552), NRCAM (ENSG00000091129), MXRA5 (ENSG00000101825), IGDCC4 (ENSG00000103742), CNTN3 (ENSG00000113805), IGSF21 (ENSG00000117154), CNTN6 (ENSG00000134115), CHL1 (ENSG00000134121), PTPRQ (ENSG00000139304), CNTN4 (ENSG00000144619), BOC (ENSG00000144857), SDK1 (ENSG00000146555), HMCN2 (ENSG00000148357), NCAM1 (ENSG00000149294), CNTN5 (ENSG00000149972), ROBO4 (ENSG00000154133), ROBO3 (ENSG00000154134), NCAM2 (ENSG00000154654), VCAM1 (ENSG00000162692), NFASC (ENSG00000163531), PRTG (ENSG00000166450), ROBO1 (ENSG00000169855), DSCAM (ENSG00000171587), IGDCC3 (ENSG00000174498), VSIG10 (ENSG00000176834), DSCAML1 (ENSG00000177103), CNTN2 (ENSG00000184144), ROBO2 (ENSG00000185008), VSIG10L (ENSG00000186806), DCC (ENSG00000187323), L1CAM (ENSG00000198910)

Protein

Protein identifiers

Immunoglobulin superfamily member 10 — Q6WRI0 (reviewed: Q6WRI0)

Alternative names: Calvaria mechanical force protein 608

All UniProt accessions (2): Q6WRI0, H7C4M2

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the control of early migration of neurons expressing gonadotropin-releasing hormone (GNRH neurons). May be involved in the maintenance of osteochondroprogenitor cells pool.

Subcellular location. Secreted.

Disease relevance. Mutations in IGSF10 may be a cause of self-limited delayed puberty. This common condition is defined as the absence of testicular enlargement in boys or breast development in girls at an age that is 2-2.5 standard deviations later than the population mean. Self-limited delayed puberty segregates within families, with the majority of families displaying an autosomal dominant pattern of inheritance.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6WRI0-1	1	yes
Q6WRI0-2	2
Q6WRI0-3	3

RefSeq proteins (5): NP_001371989, NP_001371990, NP_001371991, NP_001371992, NP_849144* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050467	LRFN	Family

Pfam: PF07679, PF13855, PF13927

UniProt features (66 total): domain 14, sequence variant 13, disulfide bond 12, glycosylation site 8, repeat 6, region of interest 4, splice variant 3, compositionally biased region 2, signal peptide 1, chain 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6WRI0-F1	58.70	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2603

Disulfide bonds (12): 497–551, 595–645, 1670–1723, 1767–1820, 1864–1917, 1963–2016, 2060–2119, 2163–2213, 2261–2313, 2359–2411, 2454–2506, 2550–2605

Glycosylation sites (8): 319, 439, 627, 774, 999, 1899, 1962, 2101

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): GOBP_NEUROGENESIS, GOLDRATH_ANTIGEN_RESPONSE, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP, GOBP_REGULATION_OF_NEURON_MIGRATION, GOBP_NEURON_MIGRATION, GOBP_OSSIFICATION, FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN, FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_DN, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP, HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_DN, chr3q25, MORI_SMALL_PRE_BII_LYMPHOCYTE_UP, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN, WONG_ADULT_TISSUE_STEM_MODULE, KIM_GLIS2_TARGETS_UP

GO Biological Process (3): ossification (GO:0001503), cell differentiation (GO:0030154), regulation of neuron migration (GO:2001222)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
multicellular organismal process	1
cellular developmental process	1
neuron migration	1
regulation of cell migration	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

786 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IGSF10	CCDC141	Q6ZP82	448
IGSF10	PROKR2	Q8NFJ6	447
IGSF10	COL12A1	Q99715	432
IGSF10	GNRH1	P01148	417
IGSF10	HS6ST1	O60243	400
IGSF10	ZNF605	Q86T29	397
IGSF10	ZSCAN29	Q8IWY8	380
IGSF10	NSMF	Q6X4W1	371
IGSF10	ANOS1	P23352	370
IGSF10	IGSF6	O95976	368
IGSF10	FNDC1	Q4ZHG4	364
IGSF10	LRRIQ3	A6PVS8	363
IGSF10	ARMCX4	Q5H9R4	348
IGSF10	IGSF1	Q8N6C5	326
IGSF10	GNRHR	P30968	324

IntAct

8 interactions, top by confidence:

A	B	Type	Score
IGSF10	HSPD1	psi-mi:“MI:0915”(physical association)	0.400
IGSF10	IGSF11	psi-mi:“MI:0915”(physical association)	0.400
IGSF10	MAG	psi-mi:“MI:0915”(physical association)	0.400
IGSF10	MILR1	psi-mi:“MI:0915”(physical association)	0.400
CD200R1L	IGSF10	psi-mi:“MI:0915”(physical association)	0.400
SIRPD	IGSF10	psi-mi:“MI:0915”(physical association)	0.400
SLAMF9	IGSF10	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (16): IGSF10 (Affinity Capture-MS), IGSF10 (Synthetic Lethality), IGSF10 (Affinity Capture-MS), IGSF10 (Proximity Label-MS), IGSF10 (Affinity Capture-MS), IGSF10 (Proximity Label-MS), NPM1 (Cross-Linking-MS (XL-MS)), RAN (Cross-Linking-MS (XL-MS)), RPL23A (Cross-Linking-MS (XL-MS)), STAU1 (Cross-Linking-MS (XL-MS)), VDAC1 (Cross-Linking-MS (XL-MS)), IGSF10 (Cross-Linking-MS (XL-MS)), IGSF10 (Cross-Linking-MS (XL-MS)), UNC13D (Cross-Linking-MS (XL-MS)), IGSF10 (Affinity Capture-RNA)

ESM2 similar proteins: A0A2R8Y4Y8, A0A2R8YFL7, A0A2R8YFM6, A0A8J1K1A4, A5D791, E7FKV8, O77726, O88393, P20239, P20783, P26342, P35054, P40200, P47984, Q03167, Q05996, Q08DT3, Q17R60, Q2Q0J1, Q3MHP9, Q3U0X8, Q3V1M1, Q4FZG8, Q4V7E2, Q5BK49, Q5SY80, Q5XI99, Q6DFV8, Q6WRH9, Q6WRI0, Q6X784, Q7TST5, Q80VH0, Q86WS3, Q8JIR8, Q8R1W8, Q925U0, Q95KG7, Q9D9J7, Q9ET62

Diamond homologs: A0N0X6, A2AJ76, A2CG49, A4IGL7, A4IIW9, B3NS99, B4GBH0, B4HNW4, B4KPU0, B4MR28, B4P5Q9, B4QC63, G5EBF1, O75325, O95428, P0C6S8, P11627, P12960, P22063, P28685, P32004, P97924, Q02246, Q07409, Q09024, Q12860, Q290N5, Q32Q07, Q3UQ28, Q3URE9, Q3V1M1, Q5R482, Q61330, Q61809, Q62682, Q62845, Q63198, Q66HV9, Q69Z26, Q6AWJ9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

724 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	498
Likely benign	121
Benign	59

Top pathogenic / likely-pathogenic (0)

SpliceAI

1339 predictions. Top by Δscore:

Variant	Effect	Δscore
3:151430288:C:CA	acceptor_gain	1.0000
3:151430292:A:AG	acceptor_gain	1.0000
3:151430296:C:G	acceptor_gain	1.0000
3:151430297:A:AG	acceptor_gain	1.0000
3:151430297:A:G	acceptor_loss	1.0000
3:151430298:G:GG	acceptor_gain	1.0000
3:151430298:GT:G	acceptor_gain	1.0000
3:151430298:GTT:G	acceptor_gain	1.0000
3:151430298:GTTT:G	acceptor_gain	1.0000
3:151430298:GTTTC:G	acceptor_gain	1.0000
3:151430376:TTCCA:T	donor_gain	1.0000
3:151430377:TCCAG:T	donor_loss	1.0000
3:151430378:CCAG:C	donor_loss	1.0000
3:151430379:CA:C	donor_gain	1.0000
3:151430379:CAGTA:C	donor_loss	1.0000
3:151430380:AGTAA:A	donor_loss	1.0000
3:151430381:G:GG	donor_gain	1.0000
3:151430382:TA:T	donor_loss	1.0000
3:151430383:AA:A	donor_loss	1.0000
3:151430384:AGTAC:A	donor_loss	1.0000
3:151444914:CATA:C	donor_loss	1.0000
3:151444915:ATACC:A	donor_loss	1.0000
3:151444916:TACCT:T	donor_loss	1.0000
3:151444917:A:T	donor_loss	1.0000
3:151444918:C:CA	donor_loss	1.0000
3:151430285:T:A	acceptor_gain	0.9900
3:151430293:T:G	acceptor_gain	0.9900
3:151430293:TTACA:T	acceptor_gain	0.9900
3:151430294:TACA:T	acceptor_gain	0.9900
3:151430295:A:AG	acceptor_gain	0.9900

AlphaMissense

17228 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:151437165:A:G	W2466R	0.997
3:151437165:A:T	W2466R	0.997
3:151443612:A:G	W1779R	0.997
3:151443612:A:T	W1779R	0.997
3:151453760:G:C	S113R	0.997
3:151453760:G:T	S113R	0.997
3:151453762:T:G	S113R	0.997
3:151437163:C:A	W2466C	0.996
3:151437163:C:G	W2466C	0.996
3:151437744:A:G	W2273R	0.996
3:151437744:A:T	W2273R	0.996
3:151443198:A:G	C1917R	0.996
3:151437336:A:C	Y2409D	0.995
3:151437450:A:G	W2371R	0.995
3:151437450:A:T	W2371R	0.995
3:151437486:A:G	C2359R	0.995
3:151437545:A:C	F2339C	0.995
3:151438347:A:G	W2072R	0.995
3:151438347:A:T	W2072R	0.995
3:151457087:A:G	L88P	0.995
3:151458583:A:G	C43R	0.995
3:151437323:G:T	A2413D	0.994
3:151437545:A:G	F2339S	0.994
3:151443022:C:A	W1975C	0.994
3:151443022:C:G	W1975C	0.994
3:151443184:A:C	S1921R	0.994
3:151443184:A:T	S1921R	0.994
3:151443186:T:G	S1921R	0.994
3:151443196:G:C	C1917W	0.994
3:151443197:C:G	C1917S	0.994

dbSNP variants (sampled 300 via entrez): RS1000029000 (3:151456794 AT>A,ATT), RS1000040776 (3:151614456 T>C), RS1000064356 (3:151523918 G>C), RS1000076116 (3:151606744 A>G), RS1000077075 (3:151491031 A>T), RS1000093733 (3:151607727 C>A,T), RS1000098579 (3:151450573 G>A,T), RS1000128313 (3:151607225 A>C), RS1000146265 (3:151607461 A>G), RS1000191615 (3:151580180 C>A,T), RS1000199792 (3:151581504 G>A), RS1000212417 (3:151501176 G>C,T), RS1000213160 (3:151545291 G>A), RS1000218359 (3:151539910 G>C), RS1000233029 (3:151462854 A>G)

Disease associations

OMIM: gene MIM:617351 | disease phenotypes: MIM:212720

GenCC curated gene-disease

Disease	Classification	Inheritance
disorder of sexual differentiation	Moderate	Autosomal dominant

Mondo (3): Martsolf syndrome 1 (MONDO:8000008), primary ovarian failure (MONDO:0005387), disorder of sexual differentiation (MONDO:0002145)

Orphanet (2): Cataract-intellectual disability-hypogonadism syndrome (Orphanet:1387), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_443	Refractive error	1.000000e-10

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D012734	Disorders of Sex Development	C12.050.351.875.253; C12.200.706.316; C12.800.316; C16.131.939.316; C19.391.119
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C536028	Martsolf syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
Benzo(a)pyrene	decreases expression, increases methylation	3
S-(1,2-dichlorovinyl)cysteine	decreases expression	2
bisphenol A	affects cotreatment, increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
trichostatin A	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
butyraldehyde	decreases expression	1
ferrous chloride	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
N-Nitrosopyrrolidine	increases expression	1
Nickel	decreases expression	1
Rotenone	increases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

87 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT03718234	PHASE1	COMPLETED	Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00485186	Not specified	WITHDRAWN	Gene Polymorphisms Influencing Steroid Synthesis and Action
NCT01875640	Not specified	COMPLETED	Decision Support for Parents Receiving Information About Child’s Rare Disease
NCT02784184	Not specified	UNKNOWN	COPENHAGEN Minipuberty Study
NCT03102554	Not specified	ENROLLING_BY_INVITATION	Genetics of Differences of Sex Development and Hypospadias
NCT03283852	Not specified	RECRUITING	Identifying New Genetic Causes to Development Disorders
NCT04195490	Not specified	UNKNOWN	Evaluation of Outcomes of Feminizing Genitoplasty in Children With Disorders of Sex Development
NCT04463316	Not specified	RECRUITING	GROWing Up With Rare GENEtic Syndromes
NCT04717349	Not specified	RECRUITING	Data Collection Study of Pediatric and Adolescent Gynecology Conditions
NCT05058781	Not specified	RECRUITING	Minipuberty in Infants Born With Potential Hypogonadism Hypogonadotrope
NCT06692049	Not specified	RECRUITING	Gonadal Tissue Cryopreservation for Fertility Preservation in Children with a Disorder of Sex Development
NCT06989593	Not specified	RECRUITING	Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary